Banner image of a Black woman, a Black man, and a Caucasian man on a purple background.

APRETUDE HAS BEEN STUDIED IN DIVERSE CLINICAL AND REAL-WORLD POPULATIONS

STUDIED IN DIVERSE CLINICAL AND REAL-WORLD POPULATIONS

  • Registrational trials

    Registrational trials

    HPTN 083 (N=4566)1

    • Safety and efficacy of APRETUDE vs TRUVADA for HIV prevention in cisgender men and transgender women
    • 87% CGM, 13% TGW; 18% Latinx (in the US), 50% Black (in the US)

    HPTN 084 (N=3224)2

    • Safety and efficacy of APRETUDE vs TRUVADA for HIV prevention in cisgender women
    • >99% CGW; 97% Black
    Special populations

    HPTN 083-01 and HPTN 084-01 (Adolescents) (N=62)

    • Safety of APRETUDE in adolescents
    • 12 to <18 years of age, weighing ≥35 kg

    HPTN 084 OLE (Pregnancy) (N=325)3

    • Initial evaluation of APRETUDE safety during pregnancy
    • 100% CGW

    Because insufficient data exist to adequately assess risk, APRETUDE should only be used in pregnancy if the expected benefit outweighs the potential risks to the fetus.

  • Real-world evidence/implementation studies

    Real-world evidence/implementation studies

    OPERA (N=764)4

    • On-time dosing, HIV testing, and HIV incidence with APRETUDE
    • 13% CGW; 29% Black, 29% Hispanic

    MHS San Francisco (N=111)5

    • Retention and adherence with APRETUDE in an urban safety-net clinic
    • 65% CGM, 19% CGW, 5% TGW, 10% Nonbinary

    UC San Diego (N=187)6

    • Implementing APRETUDE in a large, academic, hospital-based, urban HIV clinic
    • 91% CGM, 9% CGW; 47% White, 3% Black, 32% Mixed/other, 40% Hispanic

    Howard Brown (N=270)7

    • Clinical characteristics and outcomes of APRETUDE at a large PrEP clinic in the Midwest
    • 80% CGM, 9% TGW, 6% Nonbinary; 3% CGW, 2% TGM; 37% Non-Hispanic White, 25% Non-Hispanic Black, 24% Hispanic, 6% Asian, 6% Multiracial, 6% Not reported

    CAN Community Health Network (N=155)8

    • Retention with APRETUDE in 26 outpatient clinics in the US
    • 76% CGM, 17% CGW, 1% TGM, 3% TGW, 3% Other; 29% White, 34% Black, 21% Hispanic, 4% Not provided

    TRIO (N=526)9

    • APRETUDE utilization over the first 5 years of US availability, including adherence, persistence, HIV incidence, and safety of APRETUDE
    • 77% CGM, 14% CGW, 9% Transgender; 48% White, 32% Black, 13% Other, 7% Unknown

    PILLAR (N=201)10

    • Characterization of patient experiences with APRETUDE
    • 94% MSM, 6% TGM; 23% Black, 69% Not Black, 9% Missing/unknown, 39% Hispanic, 60% Not Hispanic, <2% Missing/unknown

    EBONI (N=92)11

    • Assessment of HCP perceptions when identifying, counseling, and supporting APRETUDE use in Black women
    • 28% CGM, 57% CGW, 7% Other, 8% Prefer not to answer, 1% Nonbinary; 44% Black

    Kaiser Permanente (N=180)12

    • Retention and adherence with APRETUDE in two large integrated healthcare systems
    • 92% CGM, 7% CGW, 1% Unknown; 30% White, 19% Black, 34% Hispanic, 11% Other, 6% Unknown

    Whitman-Walker Health (N=129)13

    • Retention with APRETUDE in an urban PrEP clinic
    • 52% White, 30% Black, 22% Hispanic; 81% MSM, 11% TGW, 1% CGW

Talk to a ViiV Healthcare resource to learn more about the real-world studies of APRETUDE

Speak to a resource

Banner image of a Caucasian man and a Latina woman on a green background.

Review safety data from HPTN 083 and HPTN 084

See the data

View expert discussion from colleagues

Watch Dr Koppany Visnyei discuss the efficacy and safety of APRETUDE.

View all videos

Real HCP compensated by ViiV Healthcare.

Dr. Koppany Visnyei video thumbnail.

Real HCP compensated by ViiV Healthcare.

PMUS-CBTWCNT250019

References:

  1. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595-608. doi:10.1056/NEJMoa2101016

  2. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789. doi:10.1016/S0140-6736(22)00538-4

  3. Delany-Moretlwe S; HPTN 084 Study Team. Initial evaluation of injectable cabotegravir (CAB-LA) safety during pregnancy in the HPTN 084 open-label extension. Presented at: IAS; July 25, 2024.

  4. Mills AM, Brunet L, Frost KR, et al. Real world data on on-time dosing, HIV testing and HIV acquisition from the OPERA cohort. Presented at IDWeek; October 19, 2024. https:///www.natap.org/2024/IDWeek/IDWeek_20.htm

  5. Heise MJ. High retention and adherence with rapid long-acting injectable PreP implementation in an urban safety-net clinical population. Presented at HIVR4P; October 6-10, 2024. https://www.natap.org/2024/HIVR4P/HIVR4P_28.htm

  6. Turner C, Wagner GA, Pfeil A, et al. Implementing long-acting cabotegravir for HIV PrEP in a large academic hospital-based urban HIV clinic. Presented at HIVR4P; October 6-10, 2024. https://www.natap.org/2024/HIVR4P/HIVR4P_10.htm

  7. Hazra A, Schneider J, Murray M, et al. Insurance type drives cabotegravir delays: real-world long-acting PrEP outcomes in the Midwest US. Poster presented at CROI; March 3-6, 2024. https://www.croiconference.org/wp-content/uploads/sites/2/posters/2024/1241.pdf

  8. Altamirano A, Shukla P, Barnett SK. Early real-world experience of long-acting cabotegravir (CAB) for HIV pre-exposure prophylaxis (PrEP) in a large community-based clinic network (CAN Community Health): utilization and PrEP persistence. Poster presented at: OFID; October 13, 2023.

  9. Ramgopal M, Brown C, Frick A, et al. Real-world use of cabotegravir long-acting for pre-exposure prophylaxis (PrEP): data from Trio Health cohort. Presented at IDWeek; October 16-19, 2024. https://ViiVhcmedinfo.com/medical-congress/idweek-2024/

  10. Holder H, et al. Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US. Poster presented at IDWeek; October 18, 2024.

  11. Baker DM, Nelson KL, Mocherla S, et al. Change in healthcare professionals’ identification, counseling, and adherence with black women for long-acting cabotegravir (CAB LA) for PrEP across women’s health, primary care, and infectious disease states: findings from the EBONI study. Poster presented at IDWeek; October 19, 2024. https://www.natap.org/2024/IDWeek/IDWeek_18.htm

  12. Traeger M, Leyden W, Volk J, et al. Long-acting cabotegravir PrEP uptake and persistence in a large U.S. Healthcare system. Presented at: CROI; March 12, 2025. https://www.natap.org/2025/CROI/croi_38.htm

  13. Patel RR, Golden M, Eric Kelley, et al. Feasibility of long-acting injectable cabotegravir PrEP initiation and administration by community health workers and early aspects of the PrEP injection care continuum in a primary care center in Washington, D.C. Presented at: IAS; 23-26 July 2023. https://www.prepwatch.org/resources/feasibility-of-long-acting-injectable-cabotegravir-prep-initiation-and-administration-by-community-health-workers-and-early-aspects-of-the-prep-injection-care-continuum-in-a-primary-care-center-in-wa/